文献速递乳腺癌

白蛋白结合型紫杉醇联合卡铂或吉西他滨对比吉西他滨联合卡铂一线治疗三阴性转移性乳腺癌:tnAcity研究结果

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
PubMed 文献 · Ann Oncol · 2018-01-01

tnAcity研究是一项II期随机试验,纳入191例既往未接受过化疗的转移性三阴性乳腺癌患者,按1:1:1接受白蛋白结合型紫杉醇+卡铂、白蛋白结合型紫杉醇+吉西他滨或吉西他滨+卡铂一线治疗。主要终点研究者评估的无进展生存期(PFS)在白蛋白结合型紫杉醇+卡铂组显著优于另外两组,总生存期(OS)数值上更长但无统计学差异,安全性事件主要为血液学毒性。

要点

  • 白蛋白结合型紫杉醇+卡铂组中位PFS 8.3个月,显著优于白蛋白结合型紫杉醇+吉西他滨组(5.5个月)和吉西他滨+卡铂组(6.0个月)。
  • 白蛋白结合型紫杉醇+卡铂组客观缓解率(ORR)为73%,高于另外两组的39%和44%。
  • 三组≥3级不良事件主要为血液学毒性。

核心结论

  • 一线白蛋白结合型紫杉醇联合卡铂在转移性三阴性乳腺癌中具有活性,相比白蛋白结合型紫杉醇联合吉西他滨或吉西他滨联合卡铂显著延长PFS并改善风险获益比。

研究设计与样本

  • II期随机试验纳入191例病理确诊的转移性三阴性乳腺癌且未接受过转移性乳腺癌化疗的患者,按1:1:1随机分配。
  • 患者分别接受白蛋白结合型紫杉醇125 mg/m2+卡铂AUC 2、白蛋白结合型紫杉醇125 mg/m2+吉西他滨1000 mg/m2或吉西他滨1000 mg/m2+卡铂AUC 2,均在第1、8天给药,每3周重复。

主要发现

  • 白蛋白结合型紫杉醇+卡铂组中位PFS为8.3个月,对比白蛋白结合型紫杉醇+吉西他滨组5.5个月(HR 0.59,95%CI 0.38-0.92,P=0.02)和吉西他滨+卡铂组6.0个月(HR 0.58,95%CI 0.37-0.90,P=0.02)。
  • 白蛋白结合型紫杉醇+卡铂组中位OS为16.8个月,对比白蛋白结合型紫杉醇+吉西他滨组12.1个月(HR 0.73,95%CI 0.47-1.13,P=0.16)和吉西他滨+卡铂组12.6个月(HR 0.80,95%CI 0.52-1.22,P=0.29)。
  • 白蛋白结合型紫杉醇+卡铂组、白蛋白结合型紫杉醇+吉西他滨组和吉西他滨+卡铂组的ORR分别为73%、39%和44%。
  • 三组中分别有64%、56%和50%的患者开始第6周期双药治疗。

临床怎么用

  • 对于既往未接受化疗的转移性三阴性乳腺癌患者,可考虑一线使用白蛋白结合型紫杉醇联合卡铂方案。

局限性

  • 本研究为II期试验,样本量有限,OS差异未达到统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metastatic triple-negative breast cancer (mTNBC) has a poor prognosis and aggressive clinical course. tnAcity evaluated the efficacy and safety of first-line nab-paclitaxel plus carboplatin (nab-P/C), nab-paclitaxel plus gemcitabine (nab-P/G), and gemcitabine plus carboplatin (G/C) in patients with mTNBC. PATIENTS AND METHODS: Patients with pathologically confirmed mTNBC and no prior chemotherapy for metastatic BC received (1 : 1 : 1) nab-P 125 mg/m2 plus C AUC 2, nab-P 125 mg/m2 plus G 1000 mg/m2, or G 1000 mg/m2 plus C AUC 2, all on days 1, 8 q3w. Phase II primary end point: investigator-assessed progression-free survival (PFS); secondary end points included overall response rate (ORR), overall survival (OS), percentage of patients initiating cycle 6 with doublet therapy, and safety. RESULTS: In total, 191 patients were enrolled (nab-P/C, n = 64; nab-P/G, n = 61; G/C, n = 66). PFS was significantly longer with nab-P/C versus nab-P/G [median, 8.3 versus 5.5 months; hazard ratio (HR), 0.59 [95% CI, 0.38-0.92]; P = 0.02] or G/C (median, 8.3 versus 6.0 months; HR, 0.58 [95% CI, 0.37-0.90]; P = 0.02). OS was numerically longer with nab-P/C versus nab-P/G (median, 16.8 versus 12.1 months; HR, 0.73 [95% CI, 0.47-1.13]; P = 0.16) or G/C (median, 16.8 versus 12.6 months; HR, 0.80 [95% CI, 0.52-1.22]; P = 0.29). ORR was 73%, 39%, and 44%, respectively. In the nab-P/C, nab-P/G, and G/C groups, 64%, 56%, and 50% of patients initiated cycle 6 with a doublet. Grade ≥3 adverse events were mainly hematologic. CONCLUSIONS: First-line nab-P/C was active in mTNBC and resulted in a significantly longer PFS and improved risk/benefit profile versus nab-P/G or G/C.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Yardley DA, Coleman R, Conte P, et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Ann Oncol. 2018. PMID: 29878040. doi:10.1093/annonc/mdy201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。